11801 Research Drive
70 articles with AGTC
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will be participating in the following virtual conferences: 2020 Wells Fargo Virtual Healthcare Conference (September 9-10, 2020) Sue Washer, President & Chief Executive Officer, wi
AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth Quarter and Fiscal Year End 2020 Financial Results
Applied Genetic Technologies Corporation announced that it will provide a management update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5; data from Group 5 is in advance of the full interim data analysis that the Company expects to provide in 4Q 2020 for both Groups 5 and 6.
AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program
Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene
AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the Company’s culture and clinical and pre-clinical programs.
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, announced that Sue Washer, President & Chief Executive Officer, will present at the Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11, 2020 at 10:20 am ET.
AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced next steps in the clinical development of the Company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA
By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform, Applied Genetic Technologies Corporation (AGTC) created AAVs that are more robust, purer and lower cost than any of the other methods.
Applied Genetic Technologies Corporation announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.
AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
AGTC management will host a conference call beginning at 8:00 am Eastern Time that day to review results and provide a corporate update.
AGTC And The Medical College of Wisconsin Announce Publication Of Natural History Data Examining Foveal Cone Structure In Patients With CNGB3-Associated Achromatopsia
AGTC Announces Financial Results And Business Update For The Quarter And Fiscal Year Ended June 30, 2017
AGTC To Host Fourth Quarter And Fiscal Year Financial Results Conference Call And Webcast On September 13, 2017
AGTC Files Investigational New Drug Application For The Treatment Of X-Linked Retinitis Pigmentosa Caused By Mutations In The RPGR Gene
AGTC Release: Research Published In Molecular Therapy Identifies Optimal Gene-Based Therapeutic Construct For X-Linked Retinitis Pigmentosa
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa